Landlocked developing countries (LLDCs) vs Norway: Proportion of the target population who received the final dose of
Landlocked developing countries (LLDCs)
44.0%
in 2024
Norway
91.0%
in 2024
Landlocked developing countries (LLDCs) rank
17th
Norway rank
9th
Proportion of the target population who received the final dose of over time
- Landlocked developing countries (LLDCs)
- Norway
How they compare
Norway currently reports 91.0% against 44.0% in Landlocked developing countries (LLDCs), a difference of 47.0%.
That makes Norway's figure about 2.1 times Landlocked developing countries (LLDCs)'s.
Across all 15 years both countries report, Norway has been ahead every year.
Landlocked developing countries (LLDCs) ranks 17th and Norway ranks 9th of 35 groups.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Landlocked developing countries (LLDCs) | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5.3% | 78.5% | 73.2% | Norway |
| 2020s | 28.2% | 90.6% | 62.4% | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Landlocked developing countries (LLDCs) or Norway?
- Norway, at 91.0% against 44.0% in Landlocked developing countries (LLDCs) as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Landlocked developing countries (LLDCs) and Norway?
- 47.0%, with Norway ahead.
- How many years of comparable data are there for Landlocked developing countries (LLDCs) and Norway?
- 15 years are reported by both, from 2010 to 2024.
- How do Landlocked developing countries (LLDCs) and Norway rank globally for proportion of the target population who received the final dose of?
- Landlocked developing countries (LLDCs) ranks 17th and Norway ranks 9th of 35 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.